Summit Therapeutics SMMT Return on assets
Return on assets at other companies
Other financials
Where this comes from
Calculated from Summit Therapeutics’s reported figures.
Based on trailing twelve months.
The official record: Summit Therapeutics’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Summit Therapeutics's return on assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Summit Therapeutics's return on assets?
- Summit Therapeutics (SMMT) reported return on assets of -233.8% in Q1 2026.
- How has Summit Therapeutics's return on assets changed year-over-year?
- Summit Therapeutics's return on assets decreased by 172.2% year-over-year, from -85.9% to -233.8%.
- What is the long-term trend for Summit Therapeutics's return on assets?
- Over 5 years (2020 to 2025), Summit Therapeutics's return on assets has grown at a 28.0% compound annual growth rate (CAGR), from -53% to -181.9%.
- What does return on assets mean?
- How much profit the company squeezes out of everything it owns.
- How do you interpret return on assets?
- Higher means more productive assets. Unlike ROE, it is unaffected by leverage, so a wide ROE-minus-ROA gap flags a heavily levered balance sheet.
- How does return on assets compare across companies?
- Best compared within an industry — asset intensity varies enormously across sectors. Not meaningful for banks, whose assets are largely financial.